GleamWall
中文EN

IKT Inhibikase Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1750149 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-45.1%
TTM EPS YoY-185.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-52.9%
ROA-49.2%
ROIC (approx.)-68.9%
Asset turnover—

Leverage & solvency

Liabilities / assets6.4%
Debt / equity0.00x
Current ratio15.34x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue—$0
R&D expense$29.79M$17.21M
SG&A expense$23.56M$11.38M
Operating income-$51.97M-$28.59M
Pretax income-$48,259-$27,520
Income tax$0$0
Net income-$48.26M-$27.52M
EBITDA-$51.91M-$28.56M
EPS (basic)-0.49-1.16
EPS (diluted)-0.49-1.16
Weighted avg. shares (diluted)98.31M23.71M
Banking
Net interest income$3.72M$1.07M
Balance sheet
Cash & equivalents$139.22M$56.49M
Short-term investments$39.54M$41.05M
Current assets$180.11M$98.45M
PP&E, net$0$47,100
Total assets$181.20M$98.60M
Current liabilities$8.30M$3.73M
Short-term debt$0$110,517
Total liabilities$8.30M$3.73M
Shareholders' equity$172.90M$94.87M
Shares outstanding131.69M69.36M
Cash flow statement
Operating cash flow-$27.79M-$19.15M
Capital expenditure$13,399$0
Free cash flow-$27.80M-$19.15M
Investing cash flow$2.05M-$37.00M
Financing cash flow$108.46M$103.48M
Depreciation & amortization$60,499$26,272
Stock-based compensation$15.31M$8.14M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.